In a significant development, the American Society for Radiation Oncology (ASTRO) earlier this year revised its guidelines for proton therapy for the first time in more than half a decade.
ASTRO is the foremost radiation oncology society in the world, committed to promoting excellence in patient care, driving educational opportunities and professional development, and promoting and disseminating research. As a result of its new model policy, proton therapy is now the recommended standard of care for the adolescent/young adult (AYA) population and for a broader list of conditions for thoracic, abdominal, and pelvic tumors, in addition to the conditions such as spine and pediatric cancers that were included in the organization’s previous policy in 2017. This update reflects a major stride towards improving access to proton therapy and enhancing care for an even larger population of cancer patients.
The New York Proton Center remains committed to generating and leading research supporting the broader and appropriate use of proton therapy across various disease sites. We remain steadfast in our commitment to making this advanced treatment modality more accessible and to improving outcomes for patients with cancer worldwide.
Learn more about the updated ASTRO model policy recommendations.
Learn more about proton therapy treatment at NYPC.